The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.
 
Douglas Yee
Stock and Other Ownership Interests - Apogen Biotechnologies
Honoraria - Boehringer Ingelheim; Daiichi Sankyo; Puma Biotechnology
Consulting or Advisory Role - Martell diagnostic
Research Funding - Boehringer Ingelheim
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; Bayer; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Marie Paule Sablin
Honoraria - SERVIER
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Agostina Stradella
Speakers' Bureau - Eisai; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
Other Relationship - Daiichi Sankyo; MSD
 
Meri Utriainen
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Mafalda Oliveira
Honoraria - Novartis; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Puma Biotechnology; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Roche
 
Kan Yonemori
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Yoichi Naito
Consulting or Advisory Role - Chugai Pharma; Kashiwa; Lilly; Pfizer
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Roche
 
Molly Catherine Hardebeck
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Marta Puig
Employment - Boehringer Ingelheim
 
Joy Hu
Employment - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Tsvetan Nikolov Biyukov
Employment - Boehringer Ingelheim; Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)